Safety, humoral and cellular immunogenicity after coronavirus disease-19 (COVID-19) vaccination (BNT162b2) in 12 to 18 year-old children after liver transplantation

Authors
Category Primary study
Registry of TrialsTCTR
Year 2021
This article has no abstract
Epistemonikos ID: 062a6e73f6ca0aa1affffc5f3b8118f9b227e62f
First added on: Oct 08, 2021